A new treatment improves the survival rates of patients with metastatic breast cancer

Barcelona, 3 March 2011. A clinical research trial led by Dr. Javier Cortés, the head of the BREAST CANCER Programme of the Vall d’Hebron Hospital and the VHIO, has demonstrated that eribulin (a chemotherapy drug based on Halichondria okadai, a sea sponge of animal origin) improves the prognosis of patients suffering from metastatic breast cancer. The trial, A Phase III open-label randomised study (EMBRACE) of eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer, is being published today in The Lancet, and its objective was to demonstrate the efficacy of this treatment.

Related Posts